Wall Street analysts expect that Clovis Oncology (NASDAQ:CLVS) will post earnings of ($1.70) per share for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Clovis Oncology’s earnings, with estimates ranging from ($1.89) to ($1.56). Clovis Oncology reported earnings per share of ($1.94) during the same quarter last year, which suggests a positive year over year growth rate of 12.4%. The firm is expected to report its next quarterly earnings results before the market opens on Thursday, August 1st.

According to Zacks, analysts expect that Clovis Oncology will report full-year earnings of ($6.76) per share for the current year, with EPS estimates ranging from ($7.40) to ($6.04). For the next financial year, analysts forecast that the firm will post earnings of ($5.33) per share, with EPS estimates ranging from ($6.07) to ($3.86). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Clovis Oncology.

Clovis Oncology (NASDAQ:CLVS) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.80) by $0.17. The business had revenue of $33.12 million for the quarter, compared to analyst estimates of $32.10 million. Clovis Oncology had a negative return on equity of 196.39% and a negative net margin of 342.54%. The company’s quarterly revenue was up 78.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.38) EPS.

A number of analysts have recently weighed in on the company. Credit Suisse Group reissued a “buy” rating and issued a $29.00 price objective on shares of Clovis Oncology in a research report on Wednesday, May 15th. ValuEngine cut Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. BidaskClub cut Woodward, Inc.Common Stock from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Zacks Investment Research raised Gerdau from a “sell” rating to a “hold” rating in a research report on Monday, May 13th. Finally, HC Wainwright set a $51.00 price objective on Amarin and gave the stock a “buy” rating in a research report on Wednesday, July 3rd. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $27.44.

CLVS stock traded up $0.16 during trading on Tuesday, hitting $10.79. 1,940,024 shares of the company traded hands, compared to its average volume of 1,985,120. The firm has a market capitalization of $571.92 million, a price-to-earnings ratio of -1.53 and a beta of 1.91. Clovis Oncology has a 1 year low of $10.42 and a 1 year high of $46.79. The stock has a 50-day moving average of $13.44. The company has a debt-to-equity ratio of 8.04, a current ratio of 4.39 and a quick ratio of 4.15.

In other Clovis Oncology news, insider Lindsey Rolfe sold 1,728 shares of Clovis Oncology stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $14.70, for a total transaction of $25,401.60. Following the completion of the transaction, the insider now owns 23,319 shares in the company, valued at approximately $342,789.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders have sold 2,452 shares of company stock valued at $36,261. 8.30% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Great West Life Assurance Co. Can increased its stake in Clovis Oncology by 54.8% during the 4th quarter. Great West Life Assurance Co. Can now owns 7,034 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 2,489 shares during the period. Dimensional Fund Advisors LP bought a new stake in Clovis Oncology during the 4th quarter worth approximately $5,641,000. Geode Capital Management LLC grew its stake in shares of Clovis Oncology by 7.4% during the 4th quarter. Geode Capital Management LLC now owns 572,004 shares of the biopharmaceutical company’s stock worth $10,273,000 after acquiring an additional 39,369 shares in the last quarter. Two Sigma Securities LLC bought a new position in shares of Clovis Oncology during the 4th quarter worth approximately $212,000. Finally, Squarepoint Ops LLC grew its stake in shares of Clovis Oncology by 1,049.9% during the 4th quarter. Squarepoint Ops LLC now owns 78,985 shares of the biopharmaceutical company’s stock worth $1,419,000 after acquiring an additional 72,116 shares in the last quarter. Institutional investors and hedge funds own 93.21% of the company’s stock.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Featured Story: Different Options Trading Strategies

Get a free copy of the Zacks research report on Clovis Oncology (CLVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.